Het College ter Beoordeling van Geneesmiddelen - Medicines Evaluation Boardhttp://www.cbg-meb.nl/cbg/en/human-medicines/actueelThe MEB is responsible for the authorisation of safe and effective medicinal products and for their subsequent monitoring on the Dutch market. The MEB does this by providing scientific advice, assessing marketing authorisation dossiers and promoting the safe and effective use of medicinal products.enTue, 02 Jun 2015 07:57:45 GMT(c) 2015, Het College ter Beoordeling van Geneesmiddelen (CBG). Alle rechten voorbehouden.15CBG - MEBhttp://www.cbg-meb.nl/images/rss_logo.gifhttp://www.cbg-meb.nl/cbg/enRevised policy document about points of view for a proposed judgement<p>The revised policy of the Medicines Evaluation Board (MEB) for the submission of points of view for a proposed judgement came into force on 6 May 2015.</p>http://www.cbg-meb.nl/CBG/en/human-medicines/actueel/Revised_policy_document_about_points_of_view_for_a_proposed_judgement/default.htm?utm_source=CBG-RSS-feeds&utm_medium=rss&utm_campaign=CBG-RSS-feedsThu, 28 May 2015 20:50:36 GMTDomperidone suppositories no longer available<p>It is with regret that the Medicines Evaluation Board (MEB) took note of the news that Motilium (domperidone) 30 mg suppositories will no longer be available in the Netherlands. Partly as a result of this, patients also no longer have access to other authorised domperidone suppositories.</p>http://www.cbg-meb.nl/CBG/en/human-medicines/actueel/Domperidone_suppositories_no_longer_available/default.htm?utm_source=CBG-RSS-feeds&utm_medium=rss&utm_campaign=CBG-RSS-feedsThu, 28 May 2015 20:45:11 GMT